相关实验视频
Updated: May 6, 2026

03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
5.1K
在精神疾病中减肥的GLP-1R激活剂:系统性审查和元分析
Klara Müller Alves1, Manoela Teixeira da Silva1, Caroline Kaercher Kramer2
1Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre 90035-903, Brazil.
Journal of the Endocrine Society
|November 13, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 有效地管理精神病患者的肥胖症,显著降低体重并改善代谢标志物. 这些药物耐受性良好,胃肠道副作用可控.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 代谢健康 代谢健康
背景情况:
- 肥胖症在患有精神疾病的个体中很普遍,通常由精神药物药物加剧.
- 在这个人群中,急需安全有效的药理学体重管理策略.
研究的目的:
- 系统地审查和元分析葡萄糖类-1受体激动剂 (GLP-1RAs) 对肥胖精神病患者体重和代谢结果的疗效和安全性.
- 评估GLP-1RAs对体重,BMI,腰围,葡萄糖水平和不良事件的影响.
主要方法:
- 在PubMed,Embase,Cochrane CENTRAL和ClinicalTrials.gov进行了系统的文献搜索,截至2025年5月.
- 其中包括10项随机对照试验,评估了患有精神疾病和肥胖症的成年人中的GLP-1RA.
- 数据提取和偏差风险评估由两个审稿人独立进行.
主要成果:
- GLP-1RAs显著降低了体重 (MD -5.03公斤),BMI (MD -1.59公斤/米2),腰围 (MD -3.4厘米) 和禁食葡萄糖 (MD -0.29毫摩尔/升).
- 胃肠道副作用更为常见,但通常是轻微的,并没有导致停药率增加.
结论:
- GLP-1RA在精神病患者群体的肥胖管理中有效且耐受良好,产生了相当大的体重和代谢益处.
- 对于新型药物,如西马格卢提德和提泽帕提德,需要进一步的研究,特别是在长期的标准化试验中.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Regulation of Food Intake
2.8K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.8K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

